Study design and setting
A UK, multi-centre, non-interventional cohort study involving a medical record review of 191 patients commenced on palbociclib (Ibrance®, Pfizer) through the IPP between April and December 2017 at eight participating NHS trusts (Liverpool, Manchester, Glasgow, Newcastle upon Tyne, Maidstone and Tunbridge, London, Cornwall, Brighton and Sussex). Study centres were selected pragmatically based on geographic representation, the number of patients enrolled in the IPP (minimum of 15 patients), and the ability to support the delivery of the study (see 